AnaptysBio, Inc. (ANAB)
56.18
-1.11
(-1.94%)
USD |
NASDAQ |
Aug 28, 16:00
56.18
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Gross Profit Margin (Quarterly) : 97.61% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 97.61% |
| December 31, 2025 | 99.44% |
| September 30, 2025 | 99.20% |
| June 30, 2025 | 97.30% |
| March 31, 2025 | 97.82% |
| December 31, 2024 | 98.61% |
| September 30, 2024 | 98.01% |
| June 30, 2024 | 94.58% |
| March 31, 2024 | 91.57% |
| December 31, 2023 | 93.29% |
| September 30, 2023 | 82.16% |
| June 30, 2023 | 83.03% |
| March 31, 2023 | 56.84% |
| December 31, 2022 | 91.10% |
| September 30, 2022 | 54.76% |
| June 30, 2022 | 53.04% |
| March 31, 2022 | 40.93% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | 0.00% |
| Date | Value |
|---|---|
| December 31, 2019 | 0.00% |
| September 30, 2019 | |
| June 30, 2019 | 0.00% |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | 0.00% |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.00% |
| September 30, 2017 | |
| June 30, 2017 | 0.00% |
| March 31, 2017 | |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| 4D Molecular Therapeutics, Inc. | 44.75% |
| Design Therapeutics, Inc. | -- |
| Inhibrx Biosciences, Inc. | -- |
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -1.36K% |
| Return on Assets | -7.42% |
| Return on Invested Capital | -8.28% |
| Profit Margin (Quarterly) | -206.9% |
| Operating Margin (Quarterly) | -135.5% |
| Return on Net Operating Assets | -54.22% |